Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services
Domainex is the first CRO to have installed the eProtein Discovery system Installation of Nuclera’s technology expands Domainex’s protein production servicesCambridge, UK, 04 November 2024: Nuclera, the biotechnology company ac
Nuclera closes $75 million USD financing
Series C round led by Elevage Medical Technologies. Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally.
Nuclera strengthens team with three key appointments
Dr Gordon McInroy appointed as COO, Dr Tobias Ost as SVP Product Development, and Charu Maini as SVP of People
Nuclera awarded £1.14M Innovate UK funding for development of eProtein Discovery
£790k FASST grant, in collaboration with DeepMirror, and £350k Engineering Biology grant awarded for platform development.
Nuclera Joins Tech Nation’s Future Fifty Program
Nuclera recognized as one of UK’s most exciting growth stage companies Official launch of 2024 cohort taken place at 10 Downing StreetCambridge, UK, 19 March 2024: Nuclera, the biotechnology company enabling rapid protein expres
Nuclera appoints Joseph Bertelsen as Chief Commercial Officer
Key appointment to lead global commercial launch of eProtein Discovery platform
Nuclera raises $42.5M in first close of Series B for desktop protein printer
Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, announces that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter.